Top Markets
Coin of the day
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTX
주식 순위 #36397
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused... Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
주가
$0.94
마지막 동기화: 2025-02-28
시가총액
$2.73M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Fresh Tracks Therapeutics, Inc. (FRTX)

카테고리

Fresh Tracks Therapeutics, Inc. (FRTX)의 매출
Dec 2023 기준 매출 TTM: $8.01M
Fresh Tracks Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $8.01M입니다. 2022년에 회사는 $6.94M의 수익을 올렸으며 이는 2021년의 $404.00K 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Fresh Tracks Therapeutics, Inc.의 수익 기록 (2000 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $8.01M 0.00%
2023 $8.01M 15.31%
2022 $6.94M 1,618.56%
2021 $404.00K -77.83%
2020 $1.82M -76.99%
2019 $7.92M 388.10%
2018 $1.62M -88.26%
2017 $13.82M -4.90%
2016 $14.53M -30.64%
2015 $20.95M 37.67%
2014 $15.22M 97.16%
2013 $7.72M -55.94%
2012 $17.52M -41.64%
2011 $30.02M 244.60%
2010 $8.71M -31.33%
2009 $12.69M 59.45%
2008 $7.96M 44.34%
2007 $5.51M -62.61%
2006 $14.74M 22.80%
2005 $12.00M -17.48%
2004 $14.55M 80.05%
2003 $8.08M 15.29%
2002 $7.01M -38.35%
2001 $11.37M 49.16%
2000 $7.62M 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B 157,585.49%
US
$6.02B 75,109.68%
NL
- -
CH
- -
KR
$10.11B 126,190.12%
BE